Company: TVRD
Filing Date: 2025-10-20
Form Type: S-1/A
Source: 0001104659-25-100896
Chunk: 324

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-10-20
Form: S-1/A
Chunk 324
---
 and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the provisions of this guidance and the potential impact on its financial statements and disclosures.

<div align='center'>F-16</div>

TABLE OF CONTENTS

3. Fair Value Measurements The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values (in thousands):

| ​                           | ​ | ​ | Fair Value Measurements as ofDecember 31, 2024 |   |        |   |   |   |         |   |   |   |   |   |         |   |        |   |   |   |       |   |        |   | ​ |
|:----------------------------|:--|:--|:-----------------------------------------------|:--|-------:|:--|:--|:--|:--------|:--|:--|:--|:--|:--|:--------|:--|-------:|:--|:--|:--|:------|:--|-------:|:--|:--|
| ​                           | ​ | ​ | Level 1                                        |   |        |   | ​ | ​ | Level 2 |   |   |   | ​ | ​ | Level 3 |   |        |   | ​ | ​ | Total |   |        |   | ​ |
| Financial assets:           | ​ | ​ | ​                                              | ​ |      ​ | ​ | ​ | ​ | ​       | ​ | ​ | ​ | ​ | ​ | ​       | ​ |      ​ | ​ | ​ | ​ | ​     | ​ |      ​ | ​ | ​ |
| Cash equivalents:           | ​ | ​ | ​                                              | ​ |      ​ | ​ | ​ | ​ | ​       | ​ | ​ | ​ | ​ | ​ | ​       | ​ |      ​ | ​ | ​ | ​ | ​     | ​ |      ​ | ​ | ​ |
| Money market funds          | ​ | ​ | ​                                              | $ | 31,303 | ​ | ​ | ​ | ​       | $ | — | ​ | ​ | ​ | ​       | $ |      — | ​ | ​ | ​ | ​     | $ | 31,303 | ​ | ​ |
| Total financial assets      | ​ | ​ |